Original Articles 2012-02-20

The Use of Herbal Medicine and Traditional Medicine Formulations (TMFs) for Hypertension at Traditional Medicine Hospital, Yangon

This study was done to determine the use of herbal medicines and Traditional Medicine Formulations (TMFs) for treating hypertension at Outpatients' Department (OPD) of Traditional Medicine Hospital, Yangon. This study was a cross-sectional, descriptive study in 140 hypertensive patients attending th

Original Articles 2020-09-11

Is Community Intervention Effective for Improving Maternal, Newborn and Child Health Care in Hard-to-Reach Areas of Chin State, Myanmar?

To tackle the maternal, newborn and child health (MNCH) care needs is a challenging situation in remote and hard-to-reach areas. Intervention activities focusing on strengthening community health care network through community participation and supporting Basic Health Staffs for MNCH ser

Original Articles 2020-09-14

Incidence of Snakebite in Four Townships of Yangon Region

The true incidence of snakebite in Myanmar is unknown. The current data are based on hospital returns to Ministry of Health and Sports and they are likely to be under-reported. A community-based survey is useful to know the current burden of snakebite and thus for planning and formulating str

Next Prev

Aims of MHSR Journal

• To serve as an important medium for the publication of original research in the field of medical science and health research, thus filling gaps in health knowledge for effective utilization of research findings
• To impart current medical knowledge and updated scientific information obtained from research to health professionals for better and appropriate health care management
• To disseminate recent basic, applied and social research findings among health personnel of different strata for enhancing worldwide health development

Archives   2008

Myanmar   Health   Sciences   Research   Journal

Volume   20,  Number   2

TITLE:   Seroprevalence of anti-HEV-(IgG) in apparently health adults in Yangon.
AUTHOR:   Moh Moh Htun; Khin May Oo; Khin Ohnmar Lwin; Mya Mya Aye; Kyin Kyin Sann; Myo Khin; Khin Pyone Kyi; Tian Chan Li
SOURCE:   Myanmar Health Sciences Research Journal. 2008; 20(2): 114-118
ABSTRACT:   In Myanmar, hepatitis A, B, C and E are endemic, with the disease occurring subclinically or clinically in sporadic or epidemic forms.Hepatitis E is a small, non-enveloped RNA virus that is leading cause of non-enterically-transmitted viral hepatitis worldwide. The prevalence of antibody to HEV in suspected or documented endemic region has been lower than expected (3% to 26%) and this antibody in nonendemic region has been much higher than anticipated (1% to 3%). The aim of this study was to evaluate the anti-HEV IgG seropositivity in adult study population in Yangon. A total of 84 serum samples of adults (15-60 years) comprising of 43 males and 41 females were tested for anti-HEV IgG using the recombinant baculovirus expressed Viral Like Protein (VLP) of HEV antigen ORF2 by the ELISA (Enzyme Linked Immunosorbent Assay) test. Twenty-four subjects (28.57%) comprising of 16 males and 8 females were found to be positive for anti-HEV IgG. The prevalence of HEV was variable according to age group. The highest prevalence was between 20-30 years and 30-40 years age groups.Anti-HEV positivity rate was 37.2% in male and 19.52% in female subjects. In other studies, the prevalence of anti-HEV remained constant at 10-40% in young adults with no difference between males and females. The presence of anti-HEV IgG is the evidence of past infection. The use of baculovirus expressed ORF2 apparently had a sensitive and specific rate of detection to anti-HEV. Recombinant protein test detected more than 90% of the undiluted known positive sera. Anti-HEV was associated with partial protection from hepatitis E. Anti-HEV has been found to persist as little as few months to 14 years. Recombinant protein assays can detect anti-HEV in human serum obtained 13 years after infection.
SUBJECT HEADINGS:   Seroepidemiologic Studies. Hepatitis E virus. Immunoglobulin G.
FULL TEXT: